# CBI-1214

Source: https://onco.cc/drugs/cbi-1214/  
OnCo record `cbi-1214` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBI-1214 is an experimental bispecific T cell engager from Cartography Biosciences, in phase 1 trials for microsatellite-stable or MSI-low metastatic colorectal cancer.

## Summary

CBI-1214 is a bispecific T cell engager from Cartography Biosciences. A bispecific T cell engager that binds LY6G6D on colorectal cancer cells and CD3 on T cells, linking the patient's T cells to the cancer cells to kill them. Its furthest stage is phase 1, for microsatellite-stable or MSI-low metastatic colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07321106 recruiting, started 15 January 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CBI-1214
- Modality: Bispecific T cell engager
- Mechanism: A bispecific T cell engager that binds LY6G6D on colorectal cancer cells and CD3 on T cells, linking the patient's T cells to the cancer cells to kill them.

## Sources

- Cartography Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07321106
- ClinicalTrials.gov: trials of CBI-1214: https://clinicaltrials.gov/search?intr=CBI-1214

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Cartography Biosciences](https://onco.cc/companies/cartography-biosciences/)
- trials: [A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer](https://onco.cc/trials/nct07321106/)

---
JSON: https://onco.cc/api/v1/entities/cbi-1214.json